David Pass
Chief Operating Officer bij GELESIS INC
Vermogen: 319 $ op 31-12-2023
Profiel
David Pass is currently a Director at Gelesis Srl and a Chief Operating & Commercial Officer at Gelesis, Inc. He previously worked as a Director-Marketing at Bristol-Myers Squibb Pharma Co., Vice President-Marketing at Johnson & Johnson, and Vice President-Marketing at Boehringer Ingelheim Corp.
He also briefly served as Chief Operating & Commercial Officer at Gelesis Holdings, Inc. Dr. Pass received his undergraduate and doctorate degrees from Philadelphia College of Pharmacy.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
GELESIS HOLDINGS, INC.
0.22% | 17-03-2023 | 159 627 ( 0.22% ) | 319 $ | 31-12-2023 |
Actieve functies van David Pass
| Bedrijven | Functie | Begin |
|---|---|---|
| GELESIS INC | Chief Operating Officer | 01-09-2016 |
Gelesis Srl
 Gelesis Srl BiotechnologyHealth Technology Gelesis Srl engages in the manufacture, research, and development of treatment solutions and interventions for gastrointestinal diseases. It also develops products and technologies which offers solutions to induce weight loss, improve glycemic control, and manage blood sugar levels in overweight and obese patients, including those with prediabetes and type 2 diabetes. The company was founded in 2009 and is headquartered in Calimera, Italy. | Director/Board Member | - |
Eerdere bekende functies van David Pass
| Bedrijven | Functie | Einde |
|---|---|---|
| GELESIS HOLDINGS, INC. | Chief Operating Officer | 30-10-2023 |
Boehringer Ingelheim Corp.
 Boehringer Ingelheim Corp. Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim Corp. develops, manufactures and markets health care products. It focuses in the therapeutic areas of cardiovascular disease, respiratory diseases, diseases of the central nervous system, metabolic diseases, virological diseases and oncology. The company was founded on December 8, 1986 and is headquartered in Ridgefield, CT. | Sales & Marketing | 01-08-2016 |
| JOHNSON & JOHNSON | Sales & Marketing | 01-01-2008 |
| Bristol-Myers Squibb Pharma Co. | Sales & Marketing | 01-07-2002 |
Opleiding van David Pass
| Philadelphia College of Pharmacy | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| JOHNSON & JOHNSON | Health Technology |
| GELESIS HOLDINGS, INC. | Health Technology |
| Bedrijven in privébezit | 4 |
|---|---|
Gelesis, Inc.
 Gelesis, Inc. BiotechnologyHealth Technology Gelesis, Inc. operates as a consumer-centered biotherapeutics company, which engages in the development of novel therapies to induce weight loss and metabolic disorders. Its commercial product portfolio includes Plenity, an FDA-cleared product to aid in weight management, as well as potential therapies in development for patients with Type 2 Diabetes, Non-alcoholic Fatty Liver Disease /Non-alcoholic Steatohepatitis, and Functional Constipation. The company was founded by Yishai Zohar in 2006 and is headquartered in Boston, MA. | Health Technology |
Boehringer Ingelheim Corp.
Boehringer Ingelheim Corp. Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim Corp. develops, manufactures and markets health care products. It focuses in the therapeutic areas of cardiovascular disease, respiratory diseases, diseases of the central nervous system, metabolic diseases, virological diseases and oncology. The company was founded on December 8, 1986 and is headquartered in Ridgefield, CT. | Health Technology |
| Bristol-Myers Squibb Pharma Co. | |
Gelesis Srl
Gelesis Srl BiotechnologyHealth Technology Gelesis Srl engages in the manufacture, research, and development of treatment solutions and interventions for gastrointestinal diseases. It also develops products and technologies which offers solutions to induce weight loss, improve glycemic control, and manage blood sugar levels in overweight and obese patients, including those with prediabetes and type 2 diabetes. The company was founded in 2009 and is headquartered in Calimera, Italy. | Health Technology |
